Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Studies have demonstrated that the early initiation of ACEI/ARB to patients with acute
myocardial infarction is beneficial, especially in patients combined with reduced LVEF or
mild-moderate heart failure. Therefore, ACEI/ARB is a traditional treatment for patients
post-infarction. Recent clinical trials have demonstrated that Sacubitril/Valsartan is more
beneficial than Ramipril to patients post-PCI.Besides, Sacubitril/Valsartan is also effective
for essential hypertension.This study aims to assess the effect of Sacubitril/Valsartan on
short-term prognosis in hypertensive patients with acute myocardial infarction compared
against Valsartan.